PDF Archive

Easily share your PDF documents with your contacts, on the Web and Social Networks.

Share a file Manage my documents Convert Recover PDF Search Help Contact



GLOTZ Denis .pdf


Original filename: GLOTZ_Denis.pdf
Title: annexes to the DHU FIRE project (19.10.11)
Author: NoPassword

This PDF 1.3 document has been generated by Word / Mac OS X 10.7.1 Quartz PDFContext, and has been sent on pdf-archive.com on 05/09/2016 at 13:52, from IP address 91.196.x.x. The current document download page has been viewed 396 times.
File size: 142 KB (10 pages).
Privacy: public file




Download original PDF file









Document preview


CV – Denis GLOTZ

Denis GLOTZ, M.D., Ph.D.

Professional Adress:
Hopital Saint-Louis
1 avenue Claude Vellefaux 75475 PARIS Cédex 10
Tél. 33.1.42.49.96.31.
FAX: 33.1.42.49.96.06
E-mail: denis.glotz@sls.aphp.fr

Education
1972

Bachelor of science, Paris

1980

Master of Sciences,
Université Paris VI, Paris

1981

Attestation d'Etudes Approfondies en Immunologie
Institut Pasteur, Paris

1984

M.D., Faculté de Médecine Saint-Antoine,
Université Paris VI, Paris

1990

Specialist in Nephrology, France

1990

Ph.D. thesis in Immunology,
Université Paris VI, Paris

1992

Diplome d'Habilitation à Direction de Recherches
Université Paris VI, Paris

1994

Professor of Nephrology,
Université Paris VI, Paris

Post-doctoral Training
-Internships and residencies
1979-1984

Interne des Hopitaux de Paris

1987-1991

Chef de clinique-Assistant des Hopitaux, Department of Nephrology, Hopital Broussais,
Paris

1991-1994

Praticien Hospitalo-Universitaire,
Department of Nephrology, Hopital Broussais, Paris -Research fellowship

1984-1986

Medical Biology Institute, La Jolla, CA

1986-1987

University of California San Diego, CA

Academic Appointment
1994-2004

Professor of Nephrology, Université Paris VI, Paris

2004-present Professor of Nephrology, Université Paris VII, Paris

Hospital Appointment

1988-2000

Head, Renal Transplant Unit, Service de Néphrologie Hopital Broussais, Paris

2000-2004 Head, Renal Transplant Unit, Service de Néphrologie Hopital Européen Georges Pompidou
2004-present Chief, Departement of Nephrology and Renal Transplantation, Hopital Saint-Louis, Paris
Research Activities
1988-2004

Head, Transplant Immunology group,

Unit U 430, INSERM
2004-present

Head, Transplant Immunology group,

Unit U 662, INSERM
Societies
American Society of Nephrology, European Dialysis and transplantation Association, French Society of
Immunology, French Society of Nephrology, French Society of Transplantation

Committees Assignments
1998-1994 Councilor, Board of Faculté de Medecine Broussais-Hotel Dieu
1993-present Member, regulatory Committee for stable blood-derived products, Agence du Médicament, France
1994-present Member, National Pharmacovigilance Committee, Agence du Médicament, France
1995-present Councilor, French Society of Transplantation
2010: President-elect, French-speaking Society of Transplantation

H INDEX 28

BIBLIOGRAPHY – DENIS GLOTZ
1.

Ploussard G, Chambade D, Meria P, Gaudez F, Tariel E, Verine J, et al. Biopsy-confirmed de novo renal
cell carcinoma (RCC) in renal grafts: a single-centre management experience in a 2396 recipient cohort.
BJU Int. 2011 Aug. 2;

2.

Boulanger H, Haymann JP, Fouqueray B, Mansouri R, Metivier F, Mercadal L, et al. [Cinacalcet impact on
calcium homeostasis and bone remodeling in 13 renal transplanted patients with hyperparathyroidism and
hypercalcaemia.]. Nephrol Ther. 2011 Jun. 22;

3.

Lefaucheur C, Antoine C, Suberbielle C, Glotz D. Mastering the Risk of HLA Antibodies in Kidney
Transplantation: An Algorithm Based on Pretransplant Single-Antigen Flow Bead Techniques. Am J
Transplant. 2011 Jun. 10;

4.

Abboud I, Antoine C, Gaudez F, Fieux F, Lefaucheur C, Pillebout E, et al. Pulsatile perfusion preservation
for expanded-criteria donors kidneys: Impact on delayed graft function rate. Int J Artif Organs. 2011
Jun.;34(6):513–518.

5.

Bradley JA, Baldwin WM, Bingaman A, Ellenrieder C, Gebel HM, Glotz D, et al. Antibody-Mediated
Rejection-An Ounce of Prevention Is Worth a Pound of Cure. Am J Transplant. 2011 Jun.;11(6):1131–
1139.

6.

Taflin C, Charron D, Glotz D, Mooney N. Immunological function of the endothelial cell within the setting of
organ transplantation. Immunol Lett. 2011 May 27;

7.

Ronda C, Borba SCP, Ferreira SCP, Glotz D, Ianhez LE, Rodrigues H, et al. Non-human leukocyte
antigen antibodies reactive with endothelial cells could be involved in early loss of renal allografts.
Transplant Proc. 2011 May;43(4):1345–1348.

8.

Hill GS, Nochy D, Bruneval P, Duong van Huyen JP, Glotz D, Suberbielle C, et al. Donor-Specific
Antibodies Accelerate Arteriosclerosis after Kidney Transplantation. Journal of the American Society of
Nephrology. 2011 Apr. 14;

9.

Pillebout E, Rocha F, Fardet L, Rybojad M, Verine J, Glotz D, et al. Successful outcome using rituximab
as the only immunomodulation in Henoch-Schonlein purpura: case report. Nephrol Dial Transplant. 2011
Mar. 24;:1–3.

10.

Canet E, Osman D, Lambert J, Guitton C, Heng A-E, Argaud L, et al. Acute respiratory failure in kidney
transplant recipients: a multicenter study. Crit Care. 2011 Mar. 8;15(2):R91.

11.

Venot M, Abboud I, Duboust A, Michel C, Suberbielle C, Verine J, et al. Calcineurin inhibitor-free
monotherapy in human leukocyte antigen–identical live donor renal transplantation. Transplantation. 2011
Feb. 15;91(3):330–333.

12.

Taflin C, Favier B, Baudhuin J, Savenay A, Hemon P, Bensussan A, et al. Human endothelial cells
generate Th17 and regulatory T cells under inflammatory conditions. Proc Natl Acad Sci USA. 2011 Feb.
15;108(7):2891–2896.

13.

Viglietti D, Verine J, de Castro N, Scemla A, Daudon M, Glotz D, et al. Chronic interstitial nephritis in an
HIV type-1-infected patient receiving ritonavir-boosted atazanavir. Antivir. Ther. (Lond.). 2011;16(1):119–
121.

14.

Hantz S, Garnier-Geoffroy F, Mazeron M-C, Garrigue I, Merville P, Mengelle C, et al. Drug-resistant
cytomegalovirus in transplant recipients: a French cohort study. J. Antimicrob. Chemother. 2010
Dec.;65(12):2628–2640.

15.

Dantal J, Berthoux F, Moal M-C, Rostaing L, Legendre C, Genin R, et al. Efficacy and safety of de novo or
early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of
delayed graft function: 12-month results of a randomized, multicenter trial. Transpl Int. 2010
Nov.;23(11):1084–1093.

16.

Bollée G, Martinez F, Moulin B, Meulders Q, Rougier J-P, Baumelou A, et al. Renal biopsy practice in
France: results of a nationwide study. Nephrol Dial Transplant. 2010 Nov.;25(11):3579–3585.

17.

Touzot M, Pillebout E, Matignon M, Tricot L, Viard JP, Rondeau E, et al. Renal transplantation in HIVinfected patients: the Paris experience. Am J Transplant. 2010 Oct.;10(10):2263–2269.

18.

Lefaucheur C, Loupy A, Hill GS, Andrade J, Nochy D, Antoine C, et al. Preexisting donor-specific HLA
antibodies predict outcome in kidney transplantation. Journal of the American Society of Nephrology. 2010
Aug.;21(8):1398–1406.

19.

Champion L, Durrbach A, Lang P, Delahousse M, Chauvet C, Sarfati C, et al. Fumagillin for treatment of
intestinal microsporidiosis in renal transplant recipients. Am J Transplant. 2010 Aug.;10(8):1925–1930.

20.

Glotz D, Charpentier B, Abramovicz D, Lang P, Rostaing L, Rifle G, et al. Thymoglobulin induction and
sirolimus versus tacrolimus in kidney transplant recipients receiving mycophenolate mofetil and steroids.
Transplantation. 2010 Jun. 27;89(12):1511–1517.

21.

Abboud I, Galicier L, de Labarthe A, Dossier A, Glotz D, Verine J. A paraneoplastic membranoproliferative
glomerulonephritis with isolated C3 deposits associated with hairy cell leukaemia. Nephrol Dial
Transplant. 2010 Jun.;25(6):2026–2028.

22.

Touzot M, Touzot F, Galicier L, Ripault M-P, Peraldi MN, Glotz D, et al. Polyarthritis and anemia in a
hemodialysis patient: systemic lupus erythematosus following treatment with interferon alpha. Clin
Nephrol. 2010 Apr.;73(4):318–320.

23.

Francoz C, Glotz D, Moreau R, Durand F. The evaluation of renal function and disease in patients with
cirrhosis. 2010 Apr.;52(4):605–613.

24.

Glotz D. Thymoglobulin Induction and Sirolimus Versus Tacrolimus in Kidney Transplant Recipients
Receiving Mycophenolate Mofetil and Steroids. Transplantation. 2010 Mar. 17;:1–9.

25.

Sis B, Mengel M, Haas M, Colvin RB, Halloran PF, Racusen LC, et al. Banff '09 meeting report: antibody
mediated graft deterioration and implementation of Banff working groups. Am J Transplant. 2010
Mar.;10(3):464–471.

26.

Pagnoux C, Seror R, Henegar C, Mahr A, Cohen P, Le Guern V, et al. Clinical features and outcomes in
348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between
1963 and 2005 and entered into the French Vasculitis Study Group Database. Arthritis Rheum. 2010
Feb.;62(2):616–626.

27.

Taflin C, Nochy D, Hill G, Frouget T, Rioux N, Verine J, et al. Regulatory T cells in kidney allograft
infiltrates correlate with initial inflammation and graft function. Transplantation. 2010 Jan. 27;89(2):194–
199.

28.

International Summit on Transplant Tourism and Organ Trafficking. The declaration of Istanbul on organ
trafficking and transplant tourism. Saudi J Kidney Dis Transpl. 2010 Jan.;21(1):138–147.

29.

Jordan SC, Glotz D. Is rituximab safe to use in kidney transplant patients? Am J Transplant. 2010
Jan.;10(1):8–9.

30.

Ploussard G, Mongiat-Artus P, Meria P, Tariel E, Gaudez F, de Kerviler E, et al. What is the relevance of
systematic aorto-femoral Doppler ultrasound in the preoperative assessment of patients awaiting first
kidney transplantation: a monocentric prospective study. Nephrol Dial Transplant. 2010 Jan.;25(1):270–
274.

31.

Frimat L, Cassuto-Viguier E, Provôt F, Rostaing L, Charpentier B, Akposso K, et al. Long-Term Impact of
Cyclosporin Reduction with MMF Treatment in Chronic Allograft Dysfunction: REFERENECE Study 3Year Follow Up. J Transplant. 2010;2010.

32.

Servais A, Meas-Yedid V, Toupance O, Lebranchu Y, Thierry A, Moulin B, et al. Interstitial fibrosis
quantification in renal transplant recipients randomized to continue cyclosporine or convert to sirolimus.
Am J Transplant. 2009 Nov.;9(11):2552–2560.

33.

Abboud I, Porcher R, Robin M, de Latour RP, Glotz D, Socié G, et al. Chronic kidney dysfunction in
patients alive without relapse 2 years after allogeneic hematopoietic stem cell transplantation. Biol. Blood
Marrow Transplant. 2009 Oct.;15(10):1251–1257.

34.

Albano L, Berthoux F, Moal M-C, Rostaing L, Legendre C, Genin R, et al. Incidence of delayed graft

function and wound healing complications after deceased-donor kidney transplantation is not affected by
de novo everolimus. Transplantation. 2009 Jul. 15;88(1):69–76.
35.

Lefaucheur C, Nochy D, Andrade J, Verine J, Gautreau C, Charron D, et al. Comparison of combination
Plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. Am
J Transplant. 2009 May;9(5):1099–1107.

36.

Lebranchu Y, Thierry A, Toupance O, Westeel PF, Etienne I, Thervet E, et al. Efficacy on Renal Function
of Early Conversion from Cyclosporine to Sirolimus 3 Months After Renal Transplantation: Concept Study.
American Journal of Transplantation. 2009 May;9(5):1115–1123.

37.

Peraldi M-N, Berrou J, Dulphy N, Seidowsky A, Haas P, Boissel N, et al. Oxidative stress mediates a
reduced expression of the activating receptor NKG2D in NK cells from end-stage renal disease patients. J
Immunol. 2009 Feb. 1;182(3):1696–1705.

38.

Billaud EM, Antoine C, Berge M, Abboud I, Lefeuvre S, Benammar M, et al. Management of metabolic
cytochrome P450 3A4 drug-drug interaction between everolimus and azole antifungals in a renal
transplant patient. Clin Drug Investig. 2009;29(7):481–486.

39.

Lefaucheur C, Suberbielle-Boissel C, Hill GS, Nochy D, Andrade J, Antoine C, et al. Clinical relevance of
preformed HLA donor-specific antibodies in kidney transplantation. Contributions to nephrology.
2009;162:1–12.

40.

Choukroun G, Deray G, Glotz D, Lebranchu Y, Dussol B, Bourbigot B, et al. [Incidence and management
of anemia in renal transplantation: an observational-French study]. Nephrol Ther. 2008 Dec.;4(7):575–
583.

41.

Chambade D, Meria P, Tariel E, Verine J, de Kerviler E, Peraldi MN, et al. Nephron sparing surgery is a
feasible and efficient treatment of T1a renal cell carcinoma in kidney transplant: a prospective series from
a single center. J. Urol. 2008 Nov.;180(5):2106–2109.

42.

Anglicheau D, Loupy A, Lefaucheur C, Pessione F, Létourneau I, Côté I, et al. A simple clinicohistopathological composite scoring system is highly predictive of graft outcomes in marginal donors. Am
J Transplant. 2008 Nov.;8(11):2325–2334.

43.

Tobian AAR, Shirey RS, Montgomery RA, Ness PM, King KE. The critical role of plasmapheresis in ABOincompatible renal transplantation. Transfusion. 2008 Nov.;48(11):2453–2460.

44.

Lefaucheur C, Nochy D, Glotz D. [Antibody-mediated acute rejection]. Néphrologie thérapeutique. 2008
Oct.;4 Suppl 3(S3):S188–91.

45.

Lefaucheur C, Nochy D, Amrein C, Chevalier P, Guillemain R, Cherif M, et al. Renal histopathological
lesions after lung transplantation in patients with cystic fibrosis. Am J Transplant. 2008 Sep.;8(9):1901–
1910.

46.

Hertig A, Anglicheau D, Verine J, Pallet N, Touzot M, Ancel P-Y, et al. Early epithelial phenotypic changes
predict graft fibrosis. Journal of the American Society of Nephrology. 2008 Aug.;19(8):1584–1591.

47.

Glotz D. [Post-transplantation anti-HLA antibodies: which relevance?]. Nephrol Ther. 2008 Jun. 1;4 Suppl
1:S8–S12.

48.

Solez K, Colvin RB, Racusen LC, Haas M, Sis B, Mengel M, et al. Banff 07 classification of renal allograft
pathology: updates and future directions. Am J Transplant. 2008 Apr.;8(4):753–760.

49.

Lefaucheur C, Suberbielle-Boissel C, Hill GS, Nochy D, Andrade J, Antoine C, et al. Clinical relevance of
preformed HLA donor-specific antibodies in kidney transplantation. Am J Transplant. 2008 Feb.;8(2):324–
331.

50.

Mazoyer E, Daugas E, Verine J, Pillebout E, Mourad N, Molina J-M, et al. A case report of adenovirusrelated acute interstitial nephritis in a patient with AIDS. Am J Kidney Dis. 2008 Jan.;51(1):121–126.

51.

Lefaucheur C, Nochy D, Hill GS, Suberbielle-Boissel C, Antoine C, Charron D, et al. Determinants of poor
graft outcome in patients with antibody-mediated acute rejection. Am J Transplant. 2007 Apr.;7(4):832–
841.

52.

Hertig A, Verine J, Mougenot B, Jouanneau C, Ouali N, Sebe P, et al. Risk factors for early epithelial to
mesenchymal transition in renal grafts. Am J Transplant. 2006 Dec.;6(12):2937–2946.

53.

Mai H, Champion L, Ouali N, Hertig A, Peraldi M-N, Glotz D, et al. Candida albicans arteritis transmitted
by conservative liquid after renal transplantation: a report of four cases and review of the literature.
Transplantation. 2006 Nov. 15;82(9):1163–1167.

54.

Frimat L, Cassuto-Viguier E, Charpentier B, Noël C, Provôt F, Rostaing L, et al. Impact of Cyclosporine
Reduction With MMF: A Randomized Trial in Chronic Allograft Dysfunction. The “Reference” Study. Am J
Transplant. 2006 Nov.;6(11):2725–2734.

55.

Boulanger H, Mansouri R, Gautier JF, Glotz D. Are peroxisome proliferator-activated receptors new
therapeutic targets in diabetic and non-diabetic nephropathies? Nephrol Dial Transplant. 2006
Oct.;21(10):2696–2702.

56.

Lefaucheur C, Hill GS, Amrein C, Haymann J-P, Jacquot C, Glotz D, et al. Acute oxalate nephropathy: A
new etiology for acute renal failure following nonrenal solid organ transplantation. Am J Transplant. 2006
Oct.;6(10):2516–2521.

57.

Glotz D, Lucchiari N, Pegaz-Fiornet B, Suberbielle-Boissel C. Endothelial cells as targets of allograft
rejection. Transplantation. 2006 Jul. 15;82(1 Suppl):S19–21.

58.

Si-Mohamed A, Goff JL, Désiré N, Maylin S, Glotz D, Bélec L. Detection and quantitation of BK virus DNA
by real-time polymerase chain reaction in the LT-ag gene in adult renal transplant recipients. J. Virol.
Methods. 2006 Jan.;131(1):21–27.

59.

Boulanger H, Haymann JP, Fouqueray B, Mansouri R, Metivier F, Sarfati E, et al. Therapeutic failure of
cinacalcet in a renal transplant patient presenting hyperparathyroidism with severe hypercalcaemia.
Nephrol Dial Transplant. 2005 Dec.;20(12):2865.

60.

Chalem Y, Ryckelynck J-P, Tuppin P, Verger C, Chauvé S, Glotz D, et al. Access to, and outcome of,
renal transplantation according to treatment modality of end-stage renal disease in France. Kidney Int.
2005 Jun.;67(6):2448–2453.

61.

Pillebout E, Nochy D, Hill G, Conti F, Antoine C, Calmus Y, et al. Renal histopathological lesions after
orthotopic liver transplantation (OLT). Am J Transplant. 2005 May;5(5):1120–1129.

62.

Glotz D, Antoine C, Duboust A. Antidonor antibodies and transplantation: how to deal with them before
and after transplantation. Transplantation. 2005 Feb. 15;79(3 Suppl):S30–2.

63.

Godard B, Gazagne A, Gey A, Baptiste M, Vingert B, Pegaz-Fiornet B, et al. Optimization of an elispot
assay to detect cytomegalovirus-specific CD8+ T lymphocytes. Hum Immunol. 2004 Nov.;65(11):1307–
1318.

64.

Duong Van Huyen J-P, Fornes P, Guillemain R, Amrein C, Chevalier P, Latremouille C, et al. Acute
vascular humoral rejection in a sensitized cardiac graft recipient: diagnostic value of C4d
immunofluorescence. Hum Pathol. 2004 Mar.;35(3):385–388.

65.

Vieira CA, Agarwal A, Book BK, Sidner RA, Bearden CM, Gebel HM, et al. Rituximab for reduction of antiHLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and
pharmacokinetics. Transplantation. 2004 Feb. 27;77(4):542–548.

66.

Glotz D, Antoine C, Julia P, Pegaz-Fiornet B, Duboust A, Boudjeltia S, et al. Intravenous immunoglobulins
and transplantation for patients with anti-HLA antibodies. Transpl Int. 2004 Jan.;17(1):1–8.

67.

Racusen LC, Colvin RB, Solez K, Mihatsch MJ, Halloran PF, Campbell PM, et al. Antibody-mediated
rejection criteria - an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant.
2003 Jun.;3(6):708–714.

68.

Charpentier B, Rostaing L, Berthoux F, Lang P, Civati G, Touraine J-L, et al. A three-arm study comparing
immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or
cyclosporine A in adult renal transplant recipients1. Transplantation. 2003 Mar.;75(6):844–851.

69.

Glotz D, Antoine C, Julia P, Suberbielle-Boissel C, Boudjeltia S, Fraoui R, et al. Desensitization and
subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). Am J Transplant.

2002 Sep.;2(8):758–760.
70.

Hill GS, Delahousse M, Nochy D, Thervet E, Vrtovsnik F, Rémy P, et al. Outcome of relapse in lupus
nephritis: roles of reversal of renal fibrosis and response of inflammation to therapy. Kidney Int. 2002
Jun.;61(6):2176–2186.

71.

Karpinski M, Rush D, Jeffery J, Exner M, Regele H, Dancea S, et al. Flow cytometric crossmatching in
primary renal transplant recipients with a negative anti-human globulin enhanced cytotoxicity crossmatch.
J Am Soc Nephrol. 2001 Dec. 1;12(12):2807–2814.

72.

de Labarthe A, Jacobs F, Blot F, Glotz D. Acute renal failure secondary to hydroxyethylstarch
administration in a surgical patient. Am. J. Med. 2001 Oct. 1;111(5):417–418.

73.

Mourad G, Garrigue V, Squifflet JP, Besse T, Berthoux F, Alamartine E, et al. Induction versus
noninduction in renal transplant recipients with tacrolimus-based immunosuppression. Transplantation.
2001 Sep. 27;72(6):1050–1055.

74.

Hiesse C, Busson M, Buisson C, Farahmand H, Bierling P, Benbunan M, et al. Multicenter trial of one
HLA-DR-matched or mismatched blood transfusion prior to cadaveric renal transplantation. Kidney Int.
2001 Jul. 1;60(1):341–349.

75.

Antoine C, Hill G, Glotz D, Fontanière B, Tabone E, Nochy D. [Polyomavirus and tubulointerstitial
nephropathy]. Néphrologie. 2001;22(6):317–320.

76.

Braunberger E, Cohen JL, Boyer O, Pegaz-Fiornet B, Raynal-Raschilas N, Bruneval P, et al. T-Cell
suicide gene therapy for organ transplantation: induction of long-lasting tolerance to allogeneic heart
without generalized immunosuppression. Mol Ther. 2000 Dec. 1;2(6):596–601.

77.

Montgomery RA, Zachary AA, Racusen LC, Leffell MS, King KE, Burdick J, et al. Plasmapheresis and
intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows
kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation. 2000 Sep.
27;70(6):887–895.

78.

Thomas-Vaslin V, Bellier B, Cohen JL, Boyer O, Raynal-Raschilas N, Glotz D, et al. Prolonged allograft
survival through conditional and specific ablation of alloreactive T cells expressing a suicide gene.
Transplantation. 2000 May 27;69(10):2154–2161.

79.

Lucchiari N, Panajotopoulos N, Xu C, Rodrigues H, Ianhez LE, Kalil J, et al. Antibodies eluted from
acutely rejected renal allografts bind to and activate human endothelial cells. Hum Immunol. 2000
May;61(5):518–527.

80.

Lebranchu Y, Aubert P, Bayle F, Bedrossian J, Berthoux F, Bourbigot B, et al. Could steroids be
withdrawn in renal transplant patients sequentially treated with ATG, cyclosporine, and cellcept? One-year
results of a double-blind, randomized, multicenter study comparing normal dose versus low-dose and
withdrawal of steroids. M 55002 French Study Group. Transplant Proc. 2000 Mar. 1;32(2):396–397.

81.

Thervet E, Charpentier B, Durand D, Glotz D, Lebranchu Y, Lefrançois N, et al. Early renal function
deterioration is the only predictive factor of graft failure after 1 year. Transplant Proc. 2000 Mar.
1;32(2):425–426.

82.

Antoine C, Landau A, Menoyo V, Duong JP, Duboust A, Glotz D. Efficacy and safety of lamivudine in
renal transplant patients with chronic hepatitis B. Transplant Proc. 2000 Mar.;32(2):384–385.

83.

Ball B, Mousson C, Ratignier C, Guignier F, Glotz D, Rifle G. Antibodies to vascular endothelial cells in
chronic rejection of renal allografts. Transplant Proc. 2000 Mar.;32(2):353–354.

84.

Rérolle J-P, Antoine C, Raynaud A, Beyssen B, Julia P, Duboust A, et al. Successful endoluminal
thromboaspiration of renal graft venous thrombosis. Transplant Proc. 2000 Mar.;32(2):399–400.

85.

Lahlou A, Lang P, Charpentier B, Barrou B, Glotz D, Baron C, et al. Hemolytic uremic syndrome.
Recurrence after renal transplantation. Groupe Coopératif de l'Ile-de-France (GCIF). Medicine (Baltimore).
2000 Mar.;79(2):90–102.

86.

Braunberger E, Raynal-Raschilas N, Thomas-Vaslin V, Bruneval P, Fabiani JN, Carpentier A, et al.
Tolerance induced without immunosuppression in a T-lymphocyte suicide-gene therapy cardiac allograft

model in mice. J Thorac Cardiovasc Surg. 2000 Jan.;119(1):46–51.
87.

Rérolle J-P, Antoine C, Raynaud A, Beyssen B, Julia P, Duboust A, et al. Successful endoluminal
thrombo-aspiration of renal graft venous thrombosis. Transpl Int. 2000;13(1):82–86.

88.

Nochy D, Antoine C, Fontanière B, Tabone E, Mainardi JL, Glotz D. [Urinary cytology during kidney
transplantation]. Ann Pathol. 2000;20 Suppl:S79–81.

89.

Glotz D, Antoine C, Haymann J-P, Julia P, Duboust A, Bariéty J. Intravenous immunoglobulins and kidney
transplantation in patients with anti-HLA antibodies. Adv Nephrol Necker Hosp. 2000;30:221–233.

90.

Mahoney RJ, Breggia AE. Inhibition of HLA antibody cytotoxicity by intravenous immunoglobulin G F(ab')2
dimers, monomers, and monovalent F(ab). Hum Immunol. 1999 Jun. 1;60(6):492–499.

91.

Racusen LC, Solez K, Colvin RB, Bonsib SM, Castro MC, Cavallo T, et al. The Banff 97 working
classification of renal allograft pathology. Kidney Int. 1999 Feb.;55(2):713–723.

92.

Glotz D. [Xenotransplantation: from the myth to the possible]. Néphrologie. 1999;20(4):187–188.

93.

Antoine C, Thakur S, Daugas E, Fraoui R, Boudjeltia S, Julia P, et al. Vascular microthrombosis in renal
transplant recipients treated with tacrolimus. TPS. 1998 Sep. 1;30(6):2813–2814.

94.

Shah B, Antoine C, Mercier F, Julia P, Duboust A, Glotz D. Successful kidney retransplantation after
combined liver/kidney transplantation in primary hyperoxaluria type I. Nephrol Dial Transplant. 1998
Jun.;13(6):1568–1570.

95.

Bariéty J, Nochy D, Mandet C, Jacquot C, Glotz D, Meyrier A. Podocytes undergo phenotypic changes
and express macrophagic-associated markers in idiopathic collapsing glomerulopathy. Kidney Int. 1998
Apr. 1;53(4):918–925.

96.

Schussler O, Genevaz D, Latremouille C, Goussev N, Kaveri S, Glotz D. Intravenous immunoglobulins for
therapeutic use contain anti-idiotypes against xenophile antibodies and prolong discordant graft survival.
Clin. Immunol. Immunopathol. 1998 Feb.;86(2):183–191.

97.

Latremouille C, Genevaz D, Hu MC, Schussler O, Goussef N, Mandet C, et al. Normal human
immunoglobulins for intravenous use (IVIg) delay hyperacute xenograft rejection through F(ab')2-mediated
anti-complement activity. Clin Exp Immunol. 1997 Oct.;110(1):122–126.

98.

Gauffre A, Mircheva J, Glotz D, Fillastre JP, Simon P, Beaune PH, et al. Autoantibodies against a kidney-liver protein associated with quinolone-induced acute interstitial nephritis or hepatitis. Nephrol Dial
Transplant. 1997 Sep.;12(9):1961–1962.

99.

Schussler O, Latremouille C, Genevaz D, Carpentier A, Glotz D. Normal human polyclonal
immunoglobulins for intravenous use contain anti-idiotypes against natural xenophile antibodies and
prolong discordant xenograft survival. Transplant Proc. 1997 Jan.;29(1-2):959–960.

100.

Schussler O, Lantoine F, Devynck MA, Glotz D, David-Dufilho M. Human immunoglobulins inhibit
thrombin-induced Ca2+ movements and nitric oxide production in endothelial cells. J Biol Chem. 1996
Oct. 25;271(43):26473–26476.

101.

Antoine C, Garnier JL, Duboust A, Bariéty J, Stevenson G, Glotz D. Successful treatment of
posttransplant lymphoproliferative disorder with renal graft preservation by monoclonal antibody therapy.
Transplant Proc. 1996 Oct.;28(5):2825–2826.

102.

Genevaz D, Latremouille C, Goussev N, Carpentier A, Glotz D. Normal human polyclonal
immunoglobulins delay xenograft rejection through distinct F(ab')2 and Fc mediated mechanisms.
Transplant Proc. 1996 Apr.;28(2):853–854.

103.

Kaveri S, Vassilev T, Hurez V, Lengagne R, Lefranc C, Cot S, et al. Antibodies to a conserved region of
HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal
immunoglobulin for therapeutic use. J Clin Invest. 1996 Feb. 1;97(3):865–869.

104.

Vincent F, Michel M, Marrast AC, Bensousan TA, Glotz D, Duboust A. Management of ovarian cancer in
the renal transplant recipient with cyclophosphamide used as an immunosuppressive and antineoplastic
agent. Transplant Proc. 1995 Aug.;27(4):2432.

105.

Calonge VM, Glotz D, Bouscary D, Duboust A, Bruneval P, Druet P, et al. Hemophagocytic histiocytosis
(HH) in renal transplant recipients under ciclosporin therapy: report of the first two cases. Clin Transplant.
1995 Apr.;9(2):88–91.

106.

Vincent F, Raynal N, Duboust A, Glotz D, Bariéty J. Influence of epinephrine treatment of the organ donor
on acute tubular necrosis following renal transplantation. Transplant Proc. 1995 Apr.;27(2):1649.

107.

Vincent F, Raynal N, Francois A, Belec L, Duboust A, Glotz D, et al. False-positive p24 antigenaemia
detected in renal allograft recipients: possible role of rabbit antithymocyte globulins. Transplant Proc. 1995
Apr.;27(2):1738.

108.

Garnier JL, Berger F, Martin X, Dureau G, Mornex JF, Glotz D, et al. Post-transplant B-cell lymphomas-correlation of late stage B-cell differentiation and progression of disease; treatment with chimeric
monoclonal antibody. Transplant Proc. 1995 Apr.;27(2):1777.

109.

Vincent F, Duboust A, Glotz D. Pneumatosis cystoides intestinalis and immunosuppression. Am. J.
Gastroenterol. 1995 Mar.;90(3):522–523.

110.

Guillemain R, Lavarde V, Amrein C, Chevalier P, Guinvarc'h A, Glotz D. Invasive aspergillosis after
transplantation. Transplant Proc. 1995 Feb.;27(1):1307–1309.

111.

Glotz D, Haymann J-P, Niaudet P, Lang P, Druet P, Bariéty J. Successful kidney transplantation of
immunized patients after desensitization with normal human polyclonal immunoglobulins. Transplant Proc.
1995 Feb.;27(1):1038–1039.

112.

Vincent F, Levy V, Bensousan TA, Glotz D, Duboust A, Escudier B, et al. “Spontaneous” regressions of a
metastatic adenocarcinoma transmitted by a cadaver kidney graft: support for immunotherapy? Cancer
Immunol. Immunother. 1994 Sep.;39(3):205–206.

113.

Guillemain R, Lavarde V, Amrein C, Chevalier P, Guinvarc'h A, Glotz D. [Aspergillosis and renal, heart
and lung transplantation]. Pathol. Biol. 1994 Sep.;42(7):661–669.

114.

Nochy D, Heudes D, Glotz D, Lemoine R, Gentric D, Bruneval P, et al. Preeclampsia associated focal and
segmental glomerulosclerosis and glomerular hypertrophy: a morphometric analysis. Clin Nephrol. 1994
Jul.;42(1):9–17.

115.

Sundblad A, Marcos MA, Malanchere E, Castro A, Haury M, Huetz F, et al. Observations on the mode of
action of normal immunoglobulin at high doses. Immunol Rev. 1994 Jun. 1;139:125–158.

116.

Nochy D, Glotz D, Goucha R, Pelletier L, Bariéty J. [Renal involvements in human immunodeficiency virus
infection]. La Revue du praticien. 1994 Jun. 1;44(11):1494–1499.

117.

Latremouille C, Haeffner-Cavaillon N, Goussef N, Mandet C, Hinglais N, Bruneval P, et al. Normal human
polyclonal immunoglobulins for intravenous use significantly delay hyperacute xenograft rejection.
Transplant Proc. 1994 Jun.;26(3):1285.

118.

Vincent F, Glotz D, Kreft-Jais C, Boudjeltia S, Duboust A, Bariéty J. [Acute kidney failure in a patient
treated with cyclosporine A and metronidazole following kidney transplantation]. Therapie. 1994
Feb.;49(2):155.

119.

Plainfossé MC, Grataloup C, Glotz D, Sareeh A, Beyloune-Mainardi C, Duboust A, et al. [The transplanted
kidney. Role of imaging in early non-functioning grafts]. J Radiol. 1994 Jan.;75(1):25–30.

120.

Glotz D, Haymann J-P, Sansonetti N, Francois A, Menoyo-Calonge V, Bariéty J, et al. Suppression of
HLA-specific alloantibodies by high-dose intravenous immunoglobulins (IVIg). A potential tool for
transplantation of immunized patients. Transplantation. 1993 Aug.;56(2):335–337.

121.

Vincent F, Belec L, Glotz D, Menoyo-Calonge V, Duboust A, Bariéty J. False-positive neutralizable HIV
antigens detected in organ transplant recipients. AIDS. 1993 May;7(5):741–742.

122.

Nochy D, Glotz D, Dosquet P, Pruna A, Lemoine R, Guettier C, et al. Renal lesions associated with
human immunodeficiency virus infection: North American vs. European experience. Adv Nephrol Necker
Hosp. 1993;22:269–286.

123.

Nochy D, Glotz D, Dosquet P, Pruna A, Guettier C, Weiss L, et al. Renal disease associated with HIV


Related documents


glotz denis
better understanding of transplant glomerulopathy
regulation of firearms
81812 195564 1 pb
kidney 2018brochure
best hair transplant


Related keywords